Nant cancer vaccine strategies

A method of treating a cancer patient, comprising:

• obtaining a first omics data set from a first tumor tissue of the patient and a second omics data set from a first bodily fluid sample of the patient;
• determining a first tumor microenvironment status of the first tumor tissue based on the first omics data set and a second tumor microenvironment status of a second tumor tissue based on the second omics data set;
• wherein the tumor microenvironment status are selected from a group consisting of an escape phase, an elimination phase, and an equilibrium phase;
• treating the patient with a treatment regimen that is determined based on the first and second phases of the first and second tumor tissues, respectively;
• and
• wherein the treatment regimen comprises at least one of a first pharmaceutical composition that reverts the escape phase by reducing immune suppression in a tumor microenvironment, a second pharmaceutical composition that induces the elimination phase by enhancing at least one of an adaptive immune response and an innate immune response, or a third pharmaceutical composition that maintains the equilibrium phase by biasing the adaptive immune response towards a TH1 response.